Evidence map›Paper›PMID 23819884›Full record

ArticleMalaria journal2013

In vitro chloroquine resistance for Plasmodium vivax isolates from the Western Brazilian Amazon.

Yonne F Chehuan, Monica R F Costa, Jacqueline S Costa, Maria G C Alecrim, Fátima Nogueira, Henrique Silveira, Larissa W Brasil, Gisely C Melo, Wuelton M Monteiro, Marcus V G Lacerda

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. AreBiomedicines · 2024
    Article
  5. A review of malaria molecular markers for drug resistance inFrontiers in cellular and infection microbiology · 2023
    Review
  6. Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions.International journal for parasitology. Drugs and drug resistance · 2021
    Review
  7. Molecular Surveillance andFrontiers in cellular and infection microbiology · 2021
    Article
  8. Review
  9. Influence ofAntimicrobial agents and chemotherapy · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. Genetic diversity of the Plasmodium vivax multidrug resistance 1 gene in Thai parasite populations.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2018
    Article
  14. Genetic diversity of the Plasmodium vivax phosphatidylinositol 3-kinase gene in two regions of the China-Myanmar border.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2018
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Yonne F ChehuanFundação de Medicina Tropical Dr, Heitor Vieira Dourado, Av, Pedro Teixeira, 25, Dom Pedro, Manaus, AM 69040-000, Brazil.
Monica R F Costa
Jacqueline S Costa
Maria G C Alecrim
Fátima Nogueira
Henrique Silveira
Larissa W Brasil
Gisely C Melo
Wuelton M Monteiro
Marcus V G Lacerda
Fundação de Medicina Tropical · BRUniversidade do Estado do Amazonas · BRUniversidade Nova de Lisboa · PTUniversidade Nilton Lins · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChloroquine (CQ) and primaquine (PQ) are still the drugs of choice to treat Plasmodium vivax malaria in many endemic areas, Brazil included. There is in vivo evidence for the P. vivax resistance to CQ in the Brazilian Amazon, where the increase in the proportion of P. vivax malaria parallels the increase of unusual clinical complications related to this species. In this study, in vitro CQ and mefloquine (MQ)-susceptibility of P. vivax isolates from the Western Brazilian Amazon was tested using the double-site enzyme-linked lactate dehydrogenase immunodetection (DELI) assay.

methodsA total of 112 P. vivax isolates were tested in vitro for CQ-susceptibility and out of these 47 were also tested for MQ-susceptibility. The DELI assay was used to detect P. vivax growth at 48-hour short-term culture in isolates with ring stages ranging from 50 to %. Each isolate was tested in triplicate and geometric means of IC50's was obtained. Nineteen isolates were genetically characterized for pvdhfr, pvmrp1, pvmdr1 and pvdhps candidate genes likely related to CQ resistance (10 with IC50<40 nM and 9 with IC50 >100 nM).

resultsTwelve out of 112 isolates were considered resistant to CQ, resulting in 10.7% (IC95% 5.0-16.4), while 3 out of 47 (6.4%; IC95% 0.0-12.8) were resistant to MQ. A discrete correlation was observed between IC50's of CQ and MQ (Spearman=0.294; p=0.045). For pvdhps gene, a non-synonymous mutation was found at codon 382 (S→C) in 5/8 CQ-sensitive samples and 1/9 CQ-resistant samples (p=0.027). The other molecular markers were not associated to CQ-susceptibility.

conclusionsIn vitro CQ-resistance estimated in this study, estimated by the DELI test, was very similar to that observed in clinical trials, suggesting that in vitro procedures developed by capable local laboratories are useful in the surveillance of CQ-resistance in the Amazon; concurrent Amazon P. vivax strains with both CQ and MQ resistance may be common; and a non-synonymous mutation at pvdhps codon 382 (S→C) was associated to in vitro susceptibility to CQ, needing further studies to be confirmed.

Indexed as

AdolescentAdultAntimalarialsBrazilCell SurvivalChildChloroquineFemaleHumansInhibitory Concentration 50L-Lactate DehydrogenaseMalaria, VivaxMaleMefloquineMiddle AgedMutation, MissenseAntimalarialsChloroquineL-Lactate DehydrogenaseMefloquineProtozoan Proteins

Identifiers

PMID23819884
PMCPMC3704965
OpenAlexW2144926341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.